Predict your next investment

HEALTHCARE | Drug Delivery
aradigm.com

See what CB Insights has to offer

Founded Year

1991

Stage

PIPE - VI | IPO

Total Raised

$11.5M

Market Cap

0.00B

About Aradigm Corporation

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine.

Aradigm Corporation Headquarter Location

3929 Point Eden Way

Hayward, California, 94545,

United States

510-265-9000

Latest Aradigm Corporation News

Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board of Directors

Dec 28, 2021

On Dec 28, 2021 Revolo Biotherapeutics, a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced the appointment of industry veteran Tunde Otulana, M.D., to its Board of Directors. Dr. Otulana brings more than 25 years of leadership, clinical development and regulatory strategy experience in the life sciences industry. “We are delighted to welcome Dr. Otulana’s expertise to our board of directors,” said Jonathan Rigby , Group Chief Executive Officer of Revolo Biotherapeutics. “His extensive experience in executive leadership, clinical development, and regulatory strategy particularly around allergic and pulmonary diseases will be extremely valuable as we advance our lead candidates, ‘1104 and ‘1805, through four Phase 2 clinical trials in 2022 and 2023 with the goal of revolutionizing autoimmune and allergic disease treatment.” Dr. Otulana added, “I am honored to be joining Revolo’s board of directors and provide my expertise to advance revolutionary treatments with a unique mechanism of action for resetting the immune system from a pro-inflammatory state to a regulated homeostatic state. Revolo’s therapies have the potential to provide long-term disease remission for patients suffering from autoimmune and allergic diseases, who currently rely on chronic treatments that can suppress the immune system making patients vulnerable to life threatening infections and even cancer. I look forward to offering additional perspective on clinical and regulatory strategy as well, as the company advances four Phase 2 trials next year.” Tunde Otulana, M.D., brings more than 25 years of combined experience in drug development and commercialization having served in multiple executive positions at several pharmaceutical companies, and currently as Chief Medical Officer at Veloxis Pharmaceuticals. Dr. Otulana also currently holds a Non-Executive Director position at Allergy Therapeutics, and is a Clinical Professor of Medicine, Pulmonary & Critical Care at the University of California, Davis, School of Medicine, where he has served for 22 years. Previously, Dr. Otulana served as Senior Vice President and Chief Medical Officer at several companies including Mallinckrodt Pharmaceuticals, Boehringer Ingelheim, and Aradigm Corporation. Notably, he served as Medical Officer and Medical Team Leader in the Pulmonary & Allergy Drug Products Division at the United States Food and Drug Administration (FDA) for about 7 years. Dr. Otulana received his medical degree from the University of Ibadan in Nigeria and completed residency and fellowship trainings in the UK and US.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Aradigm Corporation Patents

Aradigm Corporation has filed 34 patents.

The 3 most popular patent topics include:

  • Piperazines
  • Bacterial diseases
  • Antibiotics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/14/2019

6/8/2021

Rare diseases, Antibiotics, Piperazines, Membrane biology, Drug delivery devices

Grant

Application Date

8/14/2019

Grant Date

6/8/2021

Title

Related Topics

Rare diseases, Antibiotics, Piperazines, Membrane biology, Drug delivery devices

Status

Grant

Aradigm Corporation Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aradigm Corporation Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.